Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CORT | Corcept Therapeutics Incorporated

Index	RUT	P/E	38.21	EPS (ttm)	0.83	Insider Own	0.50%	Shs Outstand	101.96M	Perf Week	-5.47%
Market Cap	3.28B	Forward P/E	34.13	EPS next Y	0.93	Insider Trans	-22.00%	Shs Float	90.75M	Perf Month	-0.53%
Income	94.60M	PEG	-	EPS next Q	0.21	Inst Own	81.80%	Short Float / Ratio	16.31% / 24.02	Perf Quarter	44.74%
Sales	428.20M	P/S	7.65	EPS this Y	-2.10%	Inst Trans	2.21%	Short Interest	14.80M	Perf Half Y	49.88%
Book/sh	4.13	P/B	7.66	EPS next Y	16.60%	ROA	16.80%	Target Price	33.42	Perf Year	24.08%
Cash/sh	3.51	P/C	9.02	EPS next 5Y	-	ROE	19.60%	52W Range	17.86 - 34.28	Perf YTD	55.79%
Dividend	-	P/FCF	24.31	EPS past 5Y	-7.70%	ROI	19.50%	52W High	-7.69%	Beta	0.45
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	20.30%	Gross Margin	98.70%	52W Low	77.16%	ATR	0.89
Employees	299	Current Ratio	4.60	Sales Q/Q	13.80%	Oper. Margin	23.10%	RSI (14)	49.02	Volatility	3.14% 2.64%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	5.70%	Profit Margin	22.10%	Rel Volume	0.85	Prev Close	31.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 02 AMC	Payout	0.00%	Avg Volume	616.17K	Price	31.64
Recom	2.00	SMA20	-3.05%	SMA50	7.02%	SMA200	31.27%	Volume	524,357	Change	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20
Feb-02-17	Initiated	Ladenburg Thalmann	Buy	$14
Apr-21-15	Initiated	FBR Capital	Outperform	$12
Jan-13-14	Downgrade	Stifel	Buy → Hold
Aug-09-13	Downgrade	Ladenburg Thalmann	Buy → Neutral	$3.30

Show Previous Ratings

Sep-22-23 07:58AM	Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up (Zacks)
Sep-19-23 01:22PM	Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength? (Zacks)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
08:29AM	Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer (Zacks)
Sep-12-23 08:26AM	Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up (Zacks)
11:30AM	Loading…
Sep-08-23 11:30AM	Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report? (Zacks)
Sep-07-23 12:17PM	Corcept Therapeutics Inc's Meteoric Rise: Unpacking the 36% Surge in Just 3 Months (GuruFocus.com) +5.14%
11:41AM	Decoding Corcept Therapeutics (CORT)'s Market Value: An In-Depth Analysis (GuruFocus.com)
11:30AM	Why Is Zoetis (ZTS) Down 1.3% Since Last Earnings Report? (Zacks)
Sep-06-23 11:30AM	Theravance Bio (TBPH) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-01-23 11:31AM	Why Is Corcept (CORT) Up 4.8% Since Last Earnings Report? (Zacks)
Aug-31-23 11:02AM	Alkermes (ALKS) Grants Teva License to Market Generic Drug (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks)
Aug-29-23 09:40AM	Has Compugen (CGEN) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-28-23 10:45AM	Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study (Zacks)
11:51AM	Loading…
Aug-25-23 11:51AM	Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study (Zacks)
08:10AM	Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio (Zacks)
Aug-24-23 09:54AM	Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7% (Zacks)
Aug-22-23 11:56AM	Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher (Zacks)
10:18AM	Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why (Zacks)
Aug-21-23 11:12AM	Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why (Zacks)
Aug-10-23 12:20PM	Will Corcept (CORT) Gain on Rising Earnings Estimates? (Zacks)
11:50AM	Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View (Zacks)
Aug-04-23 12:34PM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 11:48AM	Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View (Zacks) +24.91%
Aug-02-23 05:35PM	Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:28PM	Corcept: Q2 Earnings Snapshot (AP Finance)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
10:02AM	Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:05PM	Loading…
Jul-17-23 04:05PM	Corcepts Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Jul-03-23 09:37AM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Could Be 27% Above Their Intrinsic Value Estimate (Simply Wall St.)
Jun-27-23 08:00AM	Journal of Clinical Oncology Publishes Results of Corcepts Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Jun-21-23 08:00PM	CORT: What does Argus have to say about CORT? (Argus Research)
Jun-09-23 11:30AM	Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? (Zacks)
Jun-07-23 09:15AM	Has Corcept Therapeutics Incorporated's (NASDAQ:CORT) Impressive Stock Performance Got Anything to Do With Its Fundamentals? (Simply Wall St.)
Jun-02-23 11:31AM	Corcept (CORT) Down 4.3% Since Last Earnings Report: Can It Rebound? (Zacks)
May-04-23 03:29PM	Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance (Zacks)
11:23AM	Q1 2023 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:25PM	Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates (Zacks)
04:18PM	Corcept: Q1 Earnings Snapshot (AP Finance)
04:05PM	Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-27-23 10:02AM	Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-26-23 08:00PM	CORT: What does Argus have to say about CORT? (Argus Research)
04:05PM	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Apr-05-23 04:05PM	Corcept Therapeutics Announces Final Results of Tender Offer (GlobeNewswire)
Apr-03-23 08:00AM	Corcept Therapeutics Announces Preliminary Results of Tender Offer (GlobeNewswire)
Mar-31-23 11:30AM	Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-30-23 11:30AM	Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report? (Zacks)
Mar-28-23 04:05PM	Corcept Therapeutics Initiates CATALYST Clinical Trial (GlobeNewswire)
Mar-27-23 08:42AM	Corcept Therapeutics (NASDAQ:CORT) stock performs better than its underlying earnings growth over last three years (Simply Wall St.)
Mar-13-23 01:37AM	5 big stock buybacks: Verisk, Con Edison \| Pro Recap (Investing.com)
Mar-06-23 08:00AM	Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock (GlobeNewswire) +10.42%
Mar-03-23 11:17AM	Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-02-23 05:45AM	Corcept Therapeutics Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Mar-01-23 11:21AM	Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
10:44AM	Q4 2022 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-23 07:55PM	Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates (Zacks)
04:05PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-24-23 06:57AM	With 71% ownership of the shares, Corcept Therapeutics Incorporated (NASDAQ:CORT) is heavily dominated by institutional owners (Simply Wall St.)
Feb-14-23 04:05PM	Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Feb-13-23 08:00AM	Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation (GlobeNewswire)
Feb-09-23 02:40PM	Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching (Simply Wall St.)
Jan-24-23 07:40AM	Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT) (Simply Wall St.) -5.79%
Jan-17-23 11:21AM	Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe (Zacks)
Jan-11-23 07:59AM	Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock? (Zacks)
Dec-29-22 07:26AM	Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? (Simply Wall St.)
Dec-20-22 09:45AM	Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term (Zacks)
Dec-09-22 05:42PM	Our 7 Top Biotech Stock Picks for 2023 (InvestorPlace) -7.08%
Dec-08-22 08:00AM	Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals (GlobeNewswire)
08:00AM	Corcept Therapeutics Provides Miricorilant Clinical Development Update (GlobeNewswire)
Nov-16-22 09:46AM	Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances (Zacks)
09:45AM	Here's Why Corcept Therapeutics (CORT) is a Strong Growth Stock (Zacks)
Nov-11-22 11:40AM	UTHR vs. CORT: Which Stock Should Value Investors Buy Now? (Zacks)
Nov-04-22 10:40AM	Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss (Zacks) -10.41%
Nov-03-22 07:25PM	Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates (Zacks)
04:05PM	Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-22 04:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire)
Oct-21-22 09:30AM	These 3 Stocks Are Winning the Bear Market -- Here's How (Motley Fool)
Oct-20-22 11:26AM	Corcept (CORT) Thrives on Korlym, Overdependence a Concern (Zacks)
Oct-18-22 08:35AM	Corcept Therapeutics (NASDAQ:CORT) jumps 6.8% this week, though earnings growth is still tracking behind three-year shareholder returns (Simply Wall St.)
Oct-17-22 06:45AM	7 Under-the-Radar Stocks With 100% Upside Potential (InvestorPlace)
Oct-12-22 09:38AM	Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS (Zacks)
Oct-11-22 04:05PM	Corcept Therapeutics Initiates DAZALS A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Sep-14-22 02:10PM	Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
Sep-10-22 10:30AM	2 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Sep-03-22 10:53AM	2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat (Motley Fool)
Sep-02-22 11:32AM	Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-25-22 11:40AM	ASRT or CORT: Which Is the Better Value Stock Right Now? (Zacks)
Aug-21-22 08:38AM	Do Corcept Therapeutics' (NASDAQ:CORT) Earnings Warrant Your Attention? (Simply Wall St.)
Aug-09-22 11:40AM	JAZZ or CORT: Which Is the Better Value Stock Right Now? (Zacks)
Aug-05-22 08:25AM	Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y (Zacks)
Aug-04-22 12:30AM	Corcept Therapeutics (CORT) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-03-22 05:35PM	Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates (Zacks)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-22 09:40AM	Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-27-22 04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (GlobeNewswire) +8.39%
Jul-22-22 07:00AM	Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals? (Simply Wall St.)
Jul-15-22 07:50AM	3 Biotech Stocks Outperforming a Bear Market (InvestorPlace)
Jul-05-22 11:14AM	Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns (Zacks)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Maduck Sean	See Remarks	Sep 19	Sale	32.48	25,000	812,000	73,610	Sep 20 06:07 PM
Robb Gary Charles	Chief Business Officer	Sep 19	Sale	32.74	5,000	163,677	21,996	Sep 20 06:06 PM
Maduck Sean	See Remarks	Sep 18	Option Exercise	3.02	25,000	75,500	98,610	Sep 20 06:07 PM
Robb Gary Charles	Chief Business Officer	Sep 14	Option Exercise	3.29	13,963	45,938	34,992	Sep 18 06:12 PM
Swisher Daniel N JR	Director	Sep 05	Option Exercise	5.86	2,200	12,892	2,200	Sep 06 07:04 PM
Swisher Daniel N JR	Director	Sep 05	Sale	32.90	2,200	72,380	0	Sep 06 07:04 PM
Lyon Joseph Douglas	Chief Accounting Officer	Sep 01	Option Exercise	11.35	5,000	56,750	10,132	Sep 06 06:21 PM
Swisher Daniel N JR	Director	Sep 01	Option Exercise	6.55	1,550	10,152	1,550	Sep 06 07:04 PM
Lyon Joseph Douglas	Chief Accounting Officer	Sep 01	Sale	32.73	5,000	163,650	5,132	Sep 06 06:21 PM
Swisher Daniel N JR	Director	Sep 01	Sale	32.73	1,550	50,731	0	Sep 06 07:04 PM
Lyon Joseph Douglas	Chief Accounting Officer	Aug 21	Option Exercise	8.83	4,588	40,508	9,720	Aug 22 06:24 PM
Lyon Joseph Douglas	Chief Accounting Officer	Aug 21	Sale	31.19	4,588	143,100	5,132	Aug 22 06:24 PM
MAHONEY DAVID L	Director	Aug 14	Sale	30.95	25,000	773,668	11,297	Aug 16 04:53 PM
Hunt Hazel	Chief Scientific Officer	Aug 14	Sale	30.89	20,455	631,753	73,146	Aug 15 04:09 PM
Hunt Hazel	Chief Scientific Officer	Aug 08	Option Exercise	3.02	50,000	151,000	123,146	Aug 09 06:15 PM
Swisher Daniel N JR	Director	Aug 07	Option Exercise	6.39	2,850	18,219	2,850	Aug 09 03:07 PM
Lyon Joseph Douglas	Chief Accounting Officer	Aug 07	Option Exercise	8.27	412	3,407	5,132	Aug 09 05:20 PM
Swisher Daniel N JR	Director	Aug 07	Sale	30.14	2,850	85,909	0	Aug 09 03:07 PM
Lyon Joseph Douglas	Chief Accounting Officer	Aug 07	Sale	31.22	412	12,863	4,720	Aug 09 05:20 PM
Maduck Sean	See Remarks	Jul 17	Option Exercise	1.92	10,000	19,200	72,698	Jul 19 04:30 PM
Lyon Joseph Douglas	Chief Accounting Officer	Jun 06	Option Exercise	11.35	10,000	113,500	15,132	Jun 07 09:17 PM
Lyon Joseph Douglas	Chief Accounting Officer	Jun 06	Sale	23.60	10,000	236,000	5,132	Jun 07 09:17 PM
Robb Gary Charles	Chief Business Officer	May 10	Sale	24.07	14,000	336,980	19,997	May 11 07:30 PM
Robb Gary Charles	Chief Business Officer	May 09	Sale	23.87	30,000	716,100	33,997	May 11 07:30 PM
MAHONEY DAVID L	Director	May 08	Option Exercise	1.74	30,000	52,200	1,239,275	May 09 04:45 PM
Robb Gary Charles	Chief Business Officer	May 05	Option Exercise	2.70	105,000	283,800	124,583	May 09 04:45 PM
Maduck Sean	See Remarks	Dec 01	Option Exercise	3.29	625	2,056	57,087	Dec 05 04:45 PM
Maduck Sean	See Remarks	Dec 01	Sale	25.28	625	15,800	56,462	Dec 05 04:45 PM
Robb Gary Charles	Chief Business Officer	Nov 23	Sale	26.03	186	4,842	21,143	Nov 23 06:30 PM
Robb Gary Charles	Chief Business Officer	Nov 22	Sale	26.03	4,814	125,308	21,329	Nov 23 06:30 PM
Robb Gary Charles	Chief Business Officer	Nov 18	Sale	26.43	13,401	354,188	26,143	Nov 21 05:15 PM
Robb Gary Charles	Chief Business Officer	Nov 17	Sale	26.06	10,000	260,600	39,544	Nov 21 05:15 PM
Maduck Sean	See Remarks	Nov 10	Option Exercise	3.29	25,000	82,250	81,462	Nov 15 04:45 PM
Maduck Sean	See Remarks	Nov 10	Sale	25.57	25,000	639,250	56,462	Nov 15 04:45 PM
Maduck Sean	See Remarks	Oct 03	Option Exercise	3.29	25,000	82,250	81,462	Oct 04 05:30 PM
Maduck Sean	See Remarks	Oct 03	Sale	25.64	25,000	641,000	56,462	Oct 04 05:30 PM
Hunt Hazel	Chief Scientific Officer	Sep 28	Option Exercise	2.08	50,000	104,000	103,143	Sep 30 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT | Corcept Therapeutics Incorporated

Upgrade your FINVIZ experience